The purpose of the document is to present key facts about the FDA’s new final rule — 21 CFR 50.22 — which allows an Institutional Review Board (IRB) to waive or alter some or all informed-consent requirements for certain clinical investigations that pose no more than minimal risk to participants.
Download
Recent Posts
- October, 2024
The Role of AI in Clinical Research: Boosting Efficiency and Addressing Compliance Challenges
- December, 2025
Working with Vulnerable Populations
Summary DOJ NIH Rules on Sensitive Data Access
Sample IRB Guidelines for Investigators – Funding Agency Stop Work Orders
Comparison of FDA Regulations (Current and Proposed) & Common Rule
Summary of Proposed Changes – FDA Regulations 21 CFR 50, 21 CFR 56, and 21 CFR 812: Protection of Human Subjects and Institutional Review Boards